Systemic anticancer therapy in gynecological cancer patients with renal dysfunction

International Journal of Gynecological Cancer

Volumn 17, Issue 4, 2007, Pages 739-763

  Li, Y F ^a,b   Fu, S ^a   Hu, W ^a   Liu, J H ^b   Finkel, K W ^c   Gershenson, D M ^a   Kavanagh, J J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Cervical cancer; Chemotherapy; Chronic kidney disease; Endometrial cancer; Estimation of creatinine clearance; Ovarian cancer; Renal dysfunction; Renal failure

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANASTROZOLE; APREPITANT; BEVACIZUMAB; BLENOXAN; BLEOMYCIN; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CIMETIDINE; CISPLATIN; CITROVORUM; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEXAMETHASONE; DIAZEPAM; DIPHENHYDRAMINE; DOCETAXEL; DOLASETRON MESILATE; DOXORUBICIN; EPIRUBICIN; EPO BIS; EPOTIN; ERLOTINIB; ETOPOSIDE; FARMARUBICIN; FLUOROURACIL; GEFITINIB; GEMCITABINE; GRANISETRON; IFOSFAMIDE; IMATINIB; INTERLEUKIN 11; IRINOTECAN; LETROZOLE; LEUPRORELIN; LORAZEPAM; MEGESTROL; MEGESTROL ACETATE; METHOTREXATE; METOCLOPRAMIDE; ONDANSETRON; OXALIPLATIN; PACLITAXEL; PALONOSETRON; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; TAMOXIFEN; TAMOXIFEN CITRATE; TOPOTECAN; TRASTUZUMAB; TROPISETRON; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; VINCRISTINE SULFATE;

BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; CONFUSION; CREATININE CLEARANCE; CYTOTOXICITY; DIALYSIS; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; GYNECOLOGIC CANCER; HEADACHE; HEMODIALYSIS; HUMAN; HYPERGLYCEMIA; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; NEPHROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; UTERINE CERVIX CANCER;

ANTINEOPLASTIC AGENTS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; KIDNEY DISEASES;

EID: 34447305521     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/j.1525-1438.2007.00847.x     Document Type: Review

References (214)

1. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996 334: 1 6.
2. Serkies K, Jassem J. Chemotherapy in the primary treatment of cervical carcinoma. Crit Rev Oncol Hematol 2005 54: 197 208.
3. Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T. Systematic review of systemic therapy for advanced or recurrent endometrial cancer. Gynecol Oncol 2006 101: 158 67.
4. Chantler C, Garnett ES, Parsons V, Veall N. Glomerular filtration rate measurement in man by the single injection methods using 51Cr-EDTA. Clin Sci 1969 37: 169 80.
5. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976 16: 31 41.
6. Chatelut E, Canal P, Brunner V et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst 1995 87: 573 80.
7. Jelliffe RW. Letter: creatinine clearance: bedside estimate. Ann Intern Med 1973 79: 604 5.
8. Wright JG, Boddy AV, Highley M, Fenwick J, McGill A, Calvert AH. Estimation of glomerular filtration rate in cancer patients. Br J Cancer 2001 84: 452 9.
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999 130: 461 70.
10. O'Reilly S, Rowinsky EK, Slichenmyer W et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996 14: 3062 73.
11. Takimoto CH, Remick SC, Sharma S et al. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol 2003 21: 2664 72.
12. Clase CM, Garg AX, Kiberd BA. Classifying kidney problems: can we avoid framing risks as diseases?. BMJ 2004 329: 912 5.
13. DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-diamminedichloroplatinum (II). Cancer Res 1973 33: 1310 5.
14. Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, Repta AJ. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 1979 63: 1515 21.
15. Gouyette A, Apchin A, Foka M, Richard JM. Pharmacokinetics of intra-arterial and intravenous cisplatin in head and neck cancer patients. Eur J Cancer Clin Oncol 1986 22: 257 63.
16. Tomita M, Aoki Y, Tanaka K. Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs. Clin Pharmacokinet 2004 43: 515 27.
17. Ribrag V, Droz JP, Morizet J, Leclercq B, Gouyette A, Chabot GG. Test dose-guided administration of cisplatin in an anephric patient: a case report. Ann Oncol 1993 4: 679 82.
18. Gouyette A, Lemoine R, Adhemar JP et al. Kinetics of cisplatin in an anuric patient undergoing hemofiltration dialysis. Cancer Treat Rep 1981 65: 665 8.
19. Gorodetsky R, Vexler A, Bar-Khaim Y, Biran H. Plasma platinum elimination in a hemodialysis patient treated with cisplatin. Ther Drug Monit 1995 17: 203 6.
20. Cho H, Imada T, Masudo K et al. Combined 5-FU and CDDP in a gastric cancer patient undergoing hemodialysis - pharmacokinetics of 5-FU and CDDP. Gan To Kagaku Ryoho 2000 27: 2135 8.
21. Watanabe R, Takiguchi Y, Moriya T et al. Feasibility of combination chemotherapy with cisplatin and etoposide for haemodialysis patients with lung cancer. Br J Cancer 2003 88: 25 30.
22. Tomita M, Kurata H, Aoki Y, Tanaka K, Kazama JJ. Pharmacokinetics of paclitaxel and cisplatin in a hemodialysis patient with recurrent ovarian cancer. Anticancer Drugs 2001 12: 485 7.
23. Sturn W, Sanwald R, Ehninger G. Pharmacokinetics of cisplatin in long-term hemodialysis treatment. Dtsch Med Wochenschr 1989 114: 337 9.
24. Ozols RF, Bundy BN, Greer BE et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003 21: 3194 200.
25. Calvert AH, Newell DR, Gumbrell LA et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989 7: 1748 56.
26. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984 44: 1693 7.
27. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev 1995 21: 33 64.
28. Egorin MJ, Van Echo DA, Tipping SJ et al. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function. Cancer Res 1984 44: 5432 8.
29. Kudelka AP, Siddik ZM, Balat O, Kavanagh JJ. Carboplatin dosimetry in renal failure. J Clin Oncol 1995 13: 2147 8.
30. Jeyabalan N, Hirte HW, Moens F. Treatment of advanced ovarian carcinoma with carboplatin and paclitaxel in a patient with renal failure. Int J Gynecol Cancer 2000 10: 463 68.
31. Watanabe M, Aoki Y, Tomita M et al. Paclitaxel and carboplatin combination chemotherapy in a hemodialysis patient with advanced ovarian cancer. Gynecol Oncol 2002 84: 335 8.
32. Chatelut E, Rostaing L, Gualano V et al. Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis- dependent renal insufficiency. Nephron 1994 66: 157 61.
33. Kurata H, Yoshiya N, Ikarashi H et al. Pharmacokinetics of carboplatin in a patient under hemodialysis. Gan To Kagaku Ryoho 1994 21: 547 50.
34. Lipp H, Bokemeyer C. Anthracyclines and other intercalating agents. In: Lipp H, ed. Anticancer drug toxicity: prevention, management and clinical pharmacokinetics. New York, NY: Marcel Dekker, 1999: 81 113.
35. Fogli S, Danesi R, Gennari A, Donati S, Conte PF, Del Tacca M. Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. Ann Oncol 2002 13: 919 27.
36. Danesi R, Fogli S, Gennari A, Conte P, Del Tacca M. Pharmacokinetic- pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Pharmacokinet 2002 41: 431 44.
37. Goto M, Yoshida H, Honda A et al. Delayed disposition of adriamycin and its active metabolite in haemodialysis patients. Eur J Clin Pharmacol 1993 44: 301 2.
38. Pfizer (Perth) Pty Limited. Prescribing information for epirubicin. Available at: http://www.pfizeroncology.com/products/ellence.aspx. Accessed Jan. 11, 2006.
39. Teeling M, Hayes Y, Fitzmaurice B, McGing P, Carney DN. Carboplatin/cyclophosphamide combination chemotherapy for advanced ovarian cancer. Semin Oncol 1992 19: 102 6.
40. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005 44: 1135 64.
41. Moore MJ. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 1991 20: 194 208.
42. Bramwell V, Calvert RT, Edwards G, Scarffe H, Crowther D. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemother Pharmacol 1979 3: 253 9.
43. Juma FD, Rogers HJ, Trounce JR. Effect of renal insufficiency on the pharmacokinetics of cyclophosphamide and some of its metabolites. Eur J Clin Pharmacol 1981 19: 443 51.
44. Haubitz M, Bohnenstengel F, Brunkhorst R, Schwab M, Hofmann U, Busse D. Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency. Kidney Int 2002 61: 1495 501.
45. Bagley CM Jr., Bostick FW, DeVita VT Jr. Clinical pharmacology of cyclophosphamide. Cancer Res 1973 33: 226 33.
46. McCune JS, Adams D, Homans AC, Guillot A, Iacono L, Stewart CF. Cyclophosphamide disposition in an anephric child. Pediatr Blood Cancer 2006 46: 99 104.
47. Wagner T, Heydrich D, Bartels H, Hohorst HJ. Effect of damaged liver parenchyma, renal insufficiency and hemodialysis on the pharmacokinetics of cyclophosphamide and its activated metabolites. Arzneimittelforschung 1980 30: 1588 92.
48. Furlanut M, Franceschi L. Pharmacology of ifosfamide. Oncology 2003 65 (Suppl. 2 2 6.
49. Corlett SA, Parker D, Chrystyn H. Pharmacokinetics of ifosfamide and its enantiomers following a single 1 h intravenous infusion of the racemate in patients with small cell lung carcinoma. Br J Clin Pharmacol 1995 39: 452 5.
50. Carlson L, Goren MP, Bush DA et al. Toxicity, pharmacokinetics, and in vitro hemodialysis clearance of ifosfamide and metabolites in an anephric pediatric patient with Wilms' tumor. Cancer Chemother Pharmacol 1998 41: 140 6.
51. Klastersky J. Side effects of ifosfamide. Oncology 2003 65 (Suppl. 2 7 10.
52. Bennett WM, Aronoff GR, Morrison G et al. Drug prescribing in renal failure: dosing guidelines for adults. Am J Kidney Dis 1983 3: 155 93.
53. Reed NS, Sadozye AH. Role of chemotherapy in the management of epithelial ovarian cancer. Expert Rev Anticancer Ther 2005 5: 139 47.
54. Grochow LB, Rowinsky EK, Johnson R et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992 20: 706 13.
55. Herben VM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996 31: 85 102.
56. Herben VM, Schoemaker E, Rosing H et al. Urinary and fecal excretion of topotecan in patients with malignant solid tumours. Cancer Chemother Pharmacol 2002 50: 59 64.
57. Herrington JD, Figueroa JA, Kirstein MN, Zamboni WC, Stewart CF. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer Chemother Pharmacol 2001 47: 89 93.
58. Iacono LC, Adams D, Homans AC, Guillot A, McCune JS, Stewart CF. Topotecan disposition in an anephric child. J Pediatr Hematol Oncol 2004 26: 596 600.
59. Stemmler J, Weise A, Hacker U, Heinemann V, Schalhorn A. Weekly irinotecan in a patient with metastatic colorectal cancer on hemodialysis due to chronic renal failure. Onkologie 2002 25: 60 3.
60. Mathijssen RH, van Alphen RJ, Verweij J et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001 7: 2182 94.
61. Ando Y, Ueoka H, Sugiyama T, Ichiki M, Shimokata K, Hasegawa Y. Polymorphisms of UDP-glucuronosyltransferase and pharmacokinetics of irinotecan. Ther Drug Monit 2002 24: 111 6.
62. Wasserman E, Myara A, Lokiec F et al. Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 1997 8: 1049 51.
63. Venook AP, Enders Klein C, Fleming G et al. A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863. Ann Oncol 2003 14: 1783 90.
64. Budakoglu B, Abali H, Uncu D, Yildirim N, Oksuzoglu B, Zengin N. Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis. J Chemother 2005 17: 452 3.
65. Dimopoulos MA, Papadimitriou C, Hamilos G et al. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol 2004 95: 695 700.
66. Moosavi AS, Gilani MM, Tehranian A, Esfahani JK. Daily low-dose oral etoposide for recurrent epithelial ovarian cancer after platinum-based therapy. J Obstet Gynaecol 2004 24: 292 3.
67. Skirvin JA, Lichtman SM. Pharmacokinetic considerations of oral chemotherapy in elderly patients with cancer. Drugs Aging 2002 19: 25 42.
68. Pfluger KH, Hahn M, Holz JB et al. Pharmacokinetics of etoposide: correlation of pharmacokinetic parameters with clinical conditions. Cancer Chemother Pharmacol 1993 31: 350 6.
69. Fleming RA, Miller AA, Stewart CF. Etoposide: an update. Clin Pharm 1989 8: 274 93.
70. Holthuis JJ, Van de Vyver FL, van Oort WJ, Verleun H, Bakaert AB, De Broe ME. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Cancer Treat Rep 1985 69: 1279 82.
71. D'Incalci M, Rossi C, Zucchetti M et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Res 1986 46: 2566 71.
72. Joel SP, Shah R, Clark PI, Slevin ML. Predicting etoposide toxicity: relationship to organ function and protein binding. J Clin Oncol 1996 14: 257 67.
73. Miyaoka K, Matsubara T, Matsumoto T, Kanda C. Pharmacokinetic study of etoposide in aged patient with non Hodgkin lymphoma receiving hemodialysis. Gan To Kagaku Ryoho 1991 18: 2325 8.
74. Arbuck SG, Douglass HO, Crom WR et al. Etoposide pharmacokinetics in patients with normal and abnormal organ function. J Clin Oncol 1986 4: 1690 5.
75. Inoue A, Saijo Y, Kikuchi T et al. Pharmacokinetic analysis of combination chemotherapy with carboplatin and etoposide in small-cell lung cancer patients undergoing hemodialysis. Ann Oncol 2004 15: 51 4.
76. Suzuki S, Koide M, Sakamoto S, Matsuo T. Pharmacokinetics of carboplatin and etoposide in a haemodialysis patient with Merkel-cell carcinoma. Nephrol Dial Transplant 1997 12: 137 40.
77. Vasey PA, McMahon L, Paul J, Reed N, Kaye SB. A phase II trial of capecitabine (Xeloda) in recurrent ovarian cancer. Br J Cancer 2003 89: 1843 8.
78. Walko CM, Lindley C. Capecitabine: a review. Clin Ther 2005 27: 23 44.
79. Judson IR, Beale PJ, Trigo JM et al. A human capecitabine excretion balance and pharmacokinetic study after administration of a single oral dose of 14C-labelled drug. Invest New Drugs 1999 17: 49 56.
80. Rustum YM, Harstrick A, Cao S et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol 1997 15: 389 400.
81. Poole C, Gardiner J, Twelves C et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002 49: 225 34.
82. O'Sullivan JM, Huddart RA, Norman AR, Nicholls J, Dearnaley DP, Horwich A. Predicting the risk of bleomycin lung toxicity in patients with germ-cell tumours. Ann Oncol 2003 14: 91 6.
83. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer 1998 78: 1061 6.
84. Jules-Elysee K, White DA. Bleomycin-induced pulmonary toxicity. Clin Chest Med 1990 11: 1 20.
85. Oken MM, Crooke ST, Elson MK, Strong JE, Shafer RB. Pharmacokinetics of bleomycin after im administration in man. Cancer Treat Rep 1981 65: 485 9.
86. Hall SW, Strong JE, Broughton A, Frazier ML, Benjamin RS. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982 9: 22 5.
87. Nuver J, Lutke Holzik MF, van Zweeden M et al. Genetic variation in the bleomycin hydrolase gene and bleomycin-induced pulmonary toxicity in germ cell cancer patients. Pharmacogenet Genomics 2005 15: 399 405.
88. Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE. Bleomycin disposition in children with cancer. Clin Pharmacol Ther 1983 33: 668 73.
89. Crooke ST, Luft F, Broughton A, Strong J, Casson K, Einhorn L. Bleomycin serum pharmacokinetics as determined by a radioimmunoassay and a microbiologic assay in a patient with compromised renal function. Cancer 1977 39: 1430 4.
90. Broughton A, Strong JE, Holoye PY, Bedrossian CW. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Cancer 1977 40: 2772 8.
91. Petrilli ES, Castaldo TW, Matutat RJ, Ballon SC, Gutierrez ML. Bleomycin pharmacology in relation to adverse effects and renal function in cervical cancer patients. Gynecol Oncol 1982 14: 350 4.
92. McLeod BF, Lawrence HJ, Smith DW, Vogt PJ, Gandara DR. Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency. Cancer 1987 60: 2617 20.
93. Olsen EA. The pharmacology of methotrexate. J Am Acad Dermatol 1991 25: 306 18.
94. Bressolle F, Bologna C, Kinowski JM, Arcos B, Sany J, Combe B. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol 1997 24: 1903 9.
95. Bressolle F, Bologna C, Kinowski JM, Sany J, Combe B. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis 1998 57: 110 3.
96. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol 1995 22: 218 23.
97. Nakamura M, Sakemi T, Nagasawa K. Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol 1999 26: 1424 5.
98. Cohen PR, Schulze KE, Nelson BR. Pancytopenia after a single intradermal infiltration of methotrexate. J Drugs Dermatol 2005 4: 648 51.
99. Chatham WW, Morgan SL, Alarcon GS. Renal failure: a risk factor for methotrexate toxicity. Arthritis Rheum 2000 43: 1185 6.
100. Tokunaga J, Kikukawa H, Nishi K et al. Pharmacokinetics of cisplatin and methotrexate in a patient suffering from advanced ureteral tumor accompanied by chronic renal failure, undergoing combined hemodialysis and systemic M-VAC chemotherapy. Gan To Kagaku Ryoho 2000 27: 2079 85.
101. Thomson AH, Daly M, Knepil J, Harden P, Symonds P. Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma. Cancer Chemother Pharmacol 1996 38: 566 70.
102. Saland JM, Leavey PJ, Bash RO, Hansch E, Arbus GS, Quigley R. Effective removal of methotrexate by high-flux hemodialysis. Pediatr Nephrol 2002 17: 825 9.
103. Veal GJ, Cole M, Errington J et al. Pharmacokinetics of dactinomycin in a pediatric patient population: a United Kingdom Children's Cancer Study Group Study. Clin Cancer Res 2005 11: 5893 9.
104. Tattersall MH, Sodergren JE, Dengupta SK, Trites DH, Modest EJ, Frei E III. Pharmacokinetics of actinoymcin D in patients with malignant melanoma. Clin Pharmacol Ther 1975 17: 701 8.
105. Longnecker SM, Donehower RC, Cates AE et al. High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 1987 71: 53 9.
106. Woo MH, Gregornik D, Shearer PD, Meyer WH, Relling MV. Pharmacokinetics of paclitaxel in an anephric patient. Cancer Chemother Pharmacol 1999 43: 92 6.
107. Vaughn DJ, Manola J, Dreicer R, See W, Levitt R, Wilding G. Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group. Cancer 2002 95: 1022 7.
108. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004 96: 1682 91.
109. Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 1999 36: 99 114.
110. Gligorov J, Lotz JP. Preclinical pharmacology of the taxanes: implications of the differences. Oncologist 2004 9 (Suppl. 2 3 8.
111. Morgan RJ Jr., Doroshow JH, Synold T et al. Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003 9: 5896 901.
112. Dimopoulos MA, Deliveliotis C, Moulopoulos LA et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology 1998 52: 56 60.
113. O'Brien ME, Wigler N, Inbar M et al. Reduced cardiaotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCI (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004 15: 440 9.
114. Vail DM, Amantea MA, Colbern GT, Martin FJ, Hilger RA, Working PK. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol 2004 31: 16 35.
115. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet 2003 42: 419 36.
116. Legha SS, Benjamin RS, Mackay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982 96: 133 9.
117. Guchelaar HJ, Richel DJ, van Knapen A. Clinical, toxicological and pharmacological aspects of gemcitabine. Cancer Treat Rev 1996 22: 15 31.
118. Venook AP, Egorin MJ, Rosner GL et al. Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565. J Clin Oncol 2000 18: 2780 7.
119. Mir O, Alexandre J, Ropert S et al. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 2005 16: 1017 21.
120. Kiani A, Kohne CH, Franz T et al. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment. Cancer Chemother Pharmacol 2003 51: 266 70.
121. Cetina L, Rivera L, Candelaria M, de la Garza J, Duenas-Gonzalez A. Chemoradiation with gemcitabine for cervical cancer in patients with renal failure. Anticancer Drugs 2004 15: 761 6.
122. Delaloge S, Llombart A, Di Palma M et al. Gemcitabine in patients with solid tumors and renal impairment: a pharmacokinetic phase I study. Am J Clin Oncol 2004 27: 289 93.
123. Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res 2000 6: 1205 18.
124. Takimoto CH, Remick SC, Sharma S et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003 30: 20 5.
125. Massari C, Brienza S, Rotarski M et al. Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal function. Cancer Chemother Pharmacol 2000 45: 157 64.
126. Chirstophidis N, Vajda FJ, Lucas I, Drummer O, Moon WJ, Louis WJ. Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokinet 1978 3: 330 6.
127. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989 16: 215 37.
128. Milano G, Etienne MC, Renee N et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994 12: 1291 5.
129. Iyer L, Ratain MJ. 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest 1999 17: 494 506.
130. Raida M, Schwabe W, Hausler P et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5′-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res 2001 7: 2832 9.
131. Lazar A, Mau-Holzmann UA, Kolb H, Reichenmiller HE, Riess O, Schomig E. Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie 2004 27: 559 62.
132. Fleming GF, Schilsky RL, Schumm LP et al. Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction. Ann Oncol 2003 14: 1142 7.
133. Gusella M, Rebeschini M, Cartei G, Ferrazzi E, Ferrari M, Padrini R. Effect of hemodialysis on the metabolic clearance of 5-fluorouracil in a patient with end-stage renal failure. Ther Drug Monit 2005 27: 816 8.
134. Rengelshausen J, Hull WE, Schwenger V, Goggelmann C, Walter-Sack I, Bommer J. Pharmacokinetics of 5-fluorouracil and its catabolites determined by 19F nuclear magnetic resonance spectroscopy for a patient on chronic hemodialysis. Am J Kidney Dis 2002 39: E10.
135. Maruyama M, Irie T, Yoshida T, Nagahama T, Sugano N, Ebuchi M. Hemodynamics at hepatoarterial infusion of 5-FU in a chronic renal failure patient maintained by hemodialysis. Gan To Kagaku Ryoho 1999 26: 2241 5.
136. Gensia Sicor Pharmaceuticals, Inc. Prescribing information for Vincristine. Available at: http://www.fda.gov/cder/foi/nda/99/75- 493_VincristineSulfate.pdf. Accessed 1999.
137. Olowu WA, Elusiyan JB, Badejo SA, Adenowo OA. Acute renal failure in African children with Burkitt's lymphoma: a comparison of two treatment regimens. Pediatr Blood Cancer 2006 46: 446 53.
138. Pandit SR, Vesole DH. Management of renal dysfunction in multiple myeloma. Curr Treat Options Oncol 2003 4: 239 46.
139. Morello KC, Wurz GT, DeGregorio MW. Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 2003 42: 361 72.
140. Wiebe VJ, Benz CC, DeGregorio MW. Clinical pharmacokinetics of drugs used in the treatment of breast cancer. Clin Pharmacokinet 1988 15: 180 93.
141. Fromson JM, Pearson S, Bramah S. The metabolism of tamoxifen (I.C.I. 46,474). II. In female patients. Xenobiotica 1973 3: 711 4.
142. Sutherland CM, Sternson LA, Muchmore JH, Ball JE, Cerise EJ. Effect of impaired renal function on tamoxifen. J Surg Oncol 1984 27: 222 3.
143. Fabian C, Sternson L, Barnett M. Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules. Cancer Treat Rep 1980 64: 765 73.
144. Tunn UW, Bargelloni U, Cosciani S, Fiaccavento G, Guazzieri S, Pagano F. Comparison of LH-RH analogue 1-month depot and 3-month depot by their hormone levels and pharmacokinetic profile in patients with advanced prostate cancer. Urol Int 1998 60 (Suppl 1 9 16 discussion 16-7.
145. Saruki K, Sekihara T, Mashimo M, Matsuo H, Sekiguchi H. Leuprorelin acetate blood levels and dialysance after the administration of sustained-release leuprorelin acetate in a dialysis case complicated by prostate cancer. Prostate 1998 34: 191 4.
146. Mizusawa H, Kontani K, Okaneya T, Yoneyama T. Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient: a case report. Hinyokika Kiyo 1997 43: 421 3.
147. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. Expert Rev Anticancer Ther 2006 6: 43 7.
148. Gaver RC, Pittman KA, Reilly CM et al. Bioequivalence evaluation of new megestrol acetate formulations in humans. Semin Oncol 1985 12: 17 9.
149. Graham KK, Mikolich DJ, Fisher AE, Posner MR, Dudley MN. Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. J Acquir Immune Defic Syndr 1994 7: 580 6.
150. Par Pharmaceutical, Inc. 2004 online Megestrol acetate oral suspension. Spring Valley, NY. Available at: http://www.parpharm.com/downloads/ megestroloral_po.pdf. Accessed April 5, 2005.
151. Boccanfuso JA, Hutton M, McAllister B. The effects of megestrol acetate on nutritional parameters in a dialysis population. J Ren Nutr 2000 10: 36 43.
152. Sioufi A, Gauducheau N, Pineau V et al. Absolute bioavailability of letrozole in healthy postmenopausal women. Biopharm Drug Dispos 1997 18: 779 89.
153. Corporation NP. FemaraTM (letrozole tablets) prescribing information. Available at: http://www.ca.novartis.com/downloads/en/products/femara_scrip_e. pdf. Accessed 2004.
154. Yates RA, Dowsett M, Fisher GV, Selen A, Wyld PJ. Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 1996 73: 543 8.
155. AstraZeneca Pharmaceuticals LP. Avilable at: http://www.arimidex.com/.
156. Chon HS, Hu W, Kavanagh JJ. Targeted therapies in gynecologic cancer. Current Cancer Drug Target 2006 in press.
157. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004 30: 255 68.
158. Nakagawa K, Tamura T, Negoro S et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003 14: 922 30.
159. Baselga J, Rischin D, Ranson M et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002 20: 4292 302.
160. Frampton JE, Easthope SE. Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer. Drugs 2004 64: 2475 92.
161. Swaisland H, Laight A, Stafford L et al. Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers. Clin Pharmacokinet 2001 40: 297 306.
162. Rossi A, Maione P, Del Gaizo F, Guerriero C, Castaldo V, Gridelli C. Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases. Lung Cancer 2005 47: 421 3.
163. Takaoka K, Kimura B, Aikawa A et al. A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib. Gan To Kagaku Ryoho 2005 32: 73 6.
164. Smith J. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer. Clin Ther 2005 27: 1513 34.
165. Pharmaceuticals, Inc., Genentech, Inc. Tarceva prescribing information. Available at: http://www.tarceva.com/tarceva/professional/prescribing/PI.jsp. Accessed Feb. 15, 2006.
166. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs 2002 62: 209 43.
167. Aoki R, Kavanagh JJ. Antineoplastic agents: classification and mechanisms of action. In: Angioli R, Bendetti Panici P, Kavanagh JJ, Pecorelli S, Penalver M, eds. Chemotherapy for gynecological neoplasms: current therapy and novel approaches. New York, NY: Marcel Dekker, Inc., 2004: 3.
168. Patton TF, Himmelstein KJ, Belt R, Bannister SJ, Sternson LA, Repta AJ. Plasma levels and urinary excretion of filterable platinum species following bolus injection and iv infusion of cis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 1978 62: 1359 62.
169. Wyeth Pharmaceuticals Inc. Prescribing information for neumega. Available at: http://www.wyeth.com/products/all.asp. Accessed Feb. 19, 2006.
170. Wright MR, Axelson JE, Rurak DW et al. Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure. Br J Clin Pharmacol 1988 26: 474 7.
171. Bateman DN. Clinical pharmacokinetics of metoclopramide. Clin Pharmacokinet 1983 8: 523 9.
172. Baxter Healthcare Corporation. Prescribing information for reglan. Available at: http://www.fda.gov/medwatch/SAFETY/2004/apr04.htm. 2003.
173. Richman AV, Narayan JL, Hirschfield JS. Acute interstitial nephritis and acute renal failure associated with cimetidine therapy. Am J Med 1981 70: 1272 4.
174. Larsson R, Erlanson P, Bodemar G et al. The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function. Br J Clin Pharmacol 1982 13: 163 70.
175. Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ. Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion. Ther Drug Monit 1980 2: 273 81.
176. Ma KW, Brown DC, Masler DS, Silvis SE. Effects of renal failure on blood levels of cimetidine. Gastroenterology 1978 74: 473 7.
177. Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985 10: 477 97.
178. Periti P, Mazzei T, Mini E. Clinical pharmacokinetics of depot leuprorelin. Clin Pharmacokinet 2002 41: 485 504.
179. Farinha A, Bica A, Tavares P. Improved bioavailability of a micronized megestrol acetate tablet formulation in humans. Drug Dev Ind Pharm 2000 26: 567 70.
180. Amgen Inc. Neupogen product information. Available at: http://www.neupogen.com/pi.html 2004. Accessed February 20, 2006.
181. Togel F, Isaac J, Westenfelder C. Hematopoietic stem cell mobilization-associated granulocytosis severely worsens acute renal failure. J Am Soc Nephrol 2004 15: 1261 7.
182. Nishida M, Fujimoto S, Toiyama K, Sato H, Hamaoka K. Effect of hematopoietic cytokines on renal function in cisplatin-induced ARF in mice. Biochem Biophys Res Commun 2004 324: 341 7.
183. Kuwabara T, Ishikawa Y, Kobayashi H, Kobayashi S, Sugiyama Y. Renal clearance of a recombinant granulocyte colony-stimulating factor, nartograstim, in rats. Pharm Res 1995 12: 1466 9.
184. Akizawa T, Shishido K, Koshikawa S. The effects and pharmacokinetics of rhG-CSF in patients with chronic renal failure. Artif Organs 1995 19: 1251 7.
185. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000 14: 1310 3.
186. Amgen Inc. Epogen product information. Available at: http://www.epogen. com/professional/resources/prescribing_information/pi.jsp10/2005. Accessed Feb. 20, 2006.
187. Markham A, Bryson HM. Epoetin alfa. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 1995 49: 232 54.
188. Deshpande PV. Ondansetron for paediatric uraemic pruritus: a case report. Pediatr Nephrol 2004 19: 694 6.
189. GlaxoSmithKline. Prescribing information for zofran. Available at: http://us.gsk.com/products/assets/us_zofran.pdf. Accessed Feb. 22, 2006.
190. Hoffmann-La Roche Limited. Prescribing information for kytril. Available at: http://www.rochecanada.com/pdf/kytrilpmE.pdf. Accessed Feb. 22, 2006.
191. Wada I, Takeda T, Sato M et al. Pharmacokinetics of granisetron in adults and children with malignant diseases. Biol Pharm Bull 2001 24: 432 5.
192. Stoltz R, Parisi S, Shah A, Macciocchi A. Pharmacokinetics, metabolism and excretion of intravenous [l4C]-palonosetron in healthy human volunteers. Biopharm Drug Dispos 2004 25: 329 37.
193. Mgi Pharma Inc. Prescribing information for aloxi. Available at: http://www.aloxi.com/channels/20.asp?id=78. Accessed Feb. 22, 2006.
194. Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000 59: 1297 315.
195. Keung AC, Landriault H, Lefebvre M et al. Pharmacokinetics and safety of single intravenous and oral doses of dolasetron mesylate in healthy women. Biopharm Drug Dispos 1997 18: 361 9.
196. Aventis Pharmaceuticals Inc. Prescribing information for anzemet. Available at: http://www.aventis-us.com/. Accessed Feb. 22, 2006.
197. Merck & Co., Inc. Aprepitant product information. Available at: http://www.merck.com/product/usa/pi_circulars/e/emend/emend_pi.pdf 2005. Accessed February 22, 2006.
198. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother 2005 39: 77 85.
199. Bergman AJ, Marbury T, Fosbinder T et al. Effect of impaired renal function and haemodialysis on the pharmacokinetics of aprepitant. Clin Pharmacokinet 2005 44: 637 47.
200. Tsuei SE, Moore RG, Ashley JJ, McBride WG. Disposition of synethetic glucocorticoids. I. Pharmacokinetics of dexamethasone in healthy adults. J Pharmacokinet Biopharm 1979 7: 249 64.
201. Workman RJ, Vaughn WK, Stone WJ. Dexamethasone suppression testing in chronic renal failure: pharmacokinetics of dexamethasone and demonstration of a normal hypothalamic-pituitary-adrenal axis. J Clin Endocrinol Metab 1986 63: 741 6.
202. AWyeth-Ayerst Company. Lorazepam produc information. Available at: http://www.biovail.com/english/products/default.asp?s=1&product= 403&viewer=doctor&state=displayProduct&country=USA 2002. Accessed March 1, 2006.
203. Morrison G, Chiang ST, Koepke HH, Walker BR. Effect of renal impairment and hemodialysis on lorazepam kinetics. Clin Pharmacol Ther 1984 35: 646 52.
204. Jones TR, McKnight GT. Use of intravenous diazepam in patients on chronic hemodialysis undergoing surgery. Am Surg 1985 51: 291 2.
205. Ochs HR, Greenblatt DJ, Kaschell HJ, Klehr U, Divoll M, Abernethy DR. Diazepam kinetics in patients with renal insufficiency or hyperthyroidism. Br J Clin Pharmacol 1981 12: 829 32.
206. Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976 1: 161 88.
207. Greiner PO, Zittoun J, Marquet J, Cheron JM. Pharmacokinetics of (-)-folinic acid after oral and intravenous administration of the racemate. Br J Clin Pharmacol 1989 28: 289 95.
208. Relling MV, Stapleton FB, Ochs J et al. Removal of methotrexate, leucovorin, and their metabolites by combined hemodialysis and hemoperfusion. Cancer 1988 62: 884 8.
209. Niikura H, Koizumi T, Ito K, Okamura K, Yaegashi N. Carboplatin-based chemotherapy in patients with gynecological malignancies on long-term hemodialysis. Anticancer Drugs 2003 14: 735 8.
210. Fazeny B, Olsen SJ, Willey T et al. Pharmacokinetic assessment of paclitaxel in an ovarian cancer patient on hemodialysis. In: Proc Am Soc Clin Oncol. Los Angeles, CA, 1995: Abstract 375.
211. Balat O, Kudelka AP, Edwards CL, Verschraegen C, Mante R, Kavanagh JJ. A case report of paclitaxel administered to a patient with platinum-refractory ovarian cancer on long-term hemodialysis. Eur J Gynaecol Oncol 1996 17: 232 3.
212. Gelderblom H, Verweij J, Brouwer E et al. Disposition of [G-(3)H]paclitaxel and cremophor EL in a patient with severely impaired renal function. Drug Metab Dispos 1999 27: 1300 5.
213. Satou T, Nishida M, Sano A, Kotake Y, Tsunoda H, Kubo T. Consecutive serum concentrations of cisplatinum in a patient with endometrial carcinoma during hemodialysis. Acta Obstet Gynaecol Jpn 1996 48: 303 6.
214. Tanabe N, Goto M, Morita H et al. Pharmacokinetics of cis-diammine-dichlor-platin in a hemodialysis patient. Cancer Invest 1991 9: 629 35.